Last reviewed: 25 September 2026. Section 194R has been in force since 1 July 2022, requiring TDS at 10% on the value of any benefit or perquisite arising from business or profession that a person provides to a resident, once the aggregate value crosses ₹20,000 in a financial year. Four years in, the section itself is well understood, but assessments and TDS surveys continue to throw up disputes on the same recurring question: how do you value a non-cash benefit, and does a particular scheme item count as a “benefit” at all, or is it a discount, a rebate, or a genuine expense reimbursement that falls outside the section altogether? With the section carried forward as Section 393(1) [Table: Sl. No. 8(iv)] of the Income-tax Act, 2025 from tax year 2026-27, businesses running dealer or channel-partner incentive schemes need a durable classification framework, not a scheme-by-scheme guess. Benefits provided up to 31 March 2026 (FY 2025-26) stay under Section 194R and the 1961 procedure, so the 1961 section numbers in this article remain correct for them; the 2025 Act equivalents are given alongside for FY 2026-27 onward.
What Section 194R actually requires
Section 194R casts an obligation on any person carrying on a business or profession who provides a benefit or perquisite, whether convertible into money or not, to a resident, arising from that resident's business or the exercise of their profession, to deduct tax at 10% before the benefit is given, once the aggregate value of such benefits to that resident exceeds ₹20,000 in a financial year. Where the benefit is entirely in kind, with no cash component from which tax can be withheld, the provider must either ensure the recipient has paid the applicable tax on the benefit before releasing it, or gross up and bear the tax itself. From tax year 2026-27 the same obligation sits in Section 393(1), Table: Sl. No. 8(iv) of the Income-tax Act, 2025, which consolidates the TDS provisions into a single section with a table rather than separate sections. The rate stays at 10% and the threshold stays at ₹20,000. Before changing when your scheme deducts or collects the tax, check the timing condition in section 393(1), Table S.No. 8(iv), and the related rules; do not assume the 1961 wording carries over word for word. The provision was introduced specifically to bring within the tax net a category of business perquisites — free products, sponsored trips, gifts, sales-target incentives — that were often not being offered for taxation by recipients even though they represented real economic value flowing from a business relationship.
The section applies only where the recipient is a resident. Incentives to non-resident dealers or distributors fall outside it and are tested under section 195 (section 393(2) from 1 April 2026) and the relevant tax treaty. This matters for foreign principals that run Indian dealer schemes through a local subsidiary: the subsidiary is usually the provider for 194R purposes, and its books need to show which entity bears each benefit. Our foreign subsidiary accounting and FEMA team sets up that trail for Indian arms of overseas groups.
The three recurring dispute areas
The first area is valuation, and it is less open than it is usually argued to be. CBDT Circular No. 12/2022 dated 16 June 2022 lays down a definite hierarchy: the value is the fair market value of the benefit or perquisite, except that where the provider has purchased the benefit before providing it the value is the purchase price, and where the provider has manufactured it the value is the price charged to its customers. GST is not to be included in that value. That answers most scheme items outright — a sponsored trip bought in from a travel agent is valued at what the sponsor paid for it, not at what the dealer or doctor would have paid to buy the same trip, and a manufactured product given away is valued at the price the manufacturer charges customers, not at cost. The genuine grey area is narrower than it looks: an item that was neither purchased nor manufactured by the provider and has no established market price, and mixed packages where only part of the spend confers a benefit on the recipient. The second area is the discount-versus-benefit line. CBDT has clarified that discounts and rebates given in the ordinary course of business, and reflected in the invoice or effectively reducing the sale price, are not “benefits” under Section 194R at all — a straightforward price reduction is not income in the hands of the buyer, so there is nothing to tax. Incentives given after the sale is already complete — a bonus trip, a gadget, a year-end hamper tied to achieving a sales target — are treated differently, since they are not a reduction in the price of what was bought but a separate item of value conferred because of the business relationship, and generally do attract 194R. The third area is reimbursement versus benefit: where a dealer or professional incurs a genuine business expense on the payer's behalf (for example, travel for a joint sales visit, billed in the payer's name) and is reimbursed, that reimbursement is excluded from 194R because it is not a benefit at all — it is the payer meeting its own cost, routed through the recipient. The dispute arises where documentation is thin: if the underlying bills are not in the payer's name, or there is no clear expense-and-reimbursement trail, the department can and does recharacterise the payment as a disguised benefit.
Table: how to classify a common scheme item
| Scheme item | Typical treatment | Why |
|---|---|---|
| Volume/quantity discount shown on the invoice | Not a benefit — no 194R | Reduces the sale price in the ordinary course; CBDT has expressly excluded this |
| Cash-back credited against a future purchase | Generally not a benefit if it reduces the effective price of a purchase | Functions as a price reduction rather than a separate item of value |
| Sponsored foreign trip for top dealers | Benefit — 194R applies, valued at the sponsor's purchase price | Conferred after the sale, not a price reduction. Bought in from a travel agent, so the purchase price is the value under Circular 12/2022 |
| Free product sample for evaluation | Benefit if the aggregate for that recipient crosses ₹20,000 | Has independent value to the recipient. Value it at the price charged to customers if you manufacture it, at purchase price if you bought it in |
| Reimbursement of travel expense for a joint client visit (bills in payer's name) | Not a benefit — no 194R | Payer is meeting its own cost; no value is conferred on the recipient |
| Product demo unit retained permanently by the dealer | Benefit — 194R applies on the unit's value | Recipient retains something of lasting value beyond the demonstration purpose |
| Sponsored travel or hospitality for a doctor or other healthcare professional | 194R applies, but deal with the prior question first | Such sponsorship is prohibited under the Uniform Code for Pharmaceutical Marketing Practices, 2024 and the NMC regulations, and the expenditure is disallowed under Explanation 1 to Section 37(1) (carried into section 34 of the 2025 Act) — Apex Laboratories Pvt Ltd v. DCIT (SC, 2022). Deducting TDS does not cure either problem |
| Incentive trip or gift for a non-resident dealer | Outside 194R | 194R covers residents only; test the payment under section 195 (section 393(2) from 1 April 2026) and the treaty |
Worked example: a dealer incentive scheme, and why the pharma version is different
A consumer durables manufacturer runs a scheme under which dealers who cross a quarterly sales target are sponsored for a domestic dealer conference (flights, hotel and conference fee), the whole package bought in from a travel agent at a cost of ₹48,000 per dealer. Across the financial year twelve dealers qualify for one trip each, and no other benefits are given to them. Because the company purchased the benefit before providing it, Circular No. 12/2022 fixes the value at the purchase price of ₹48,000, GST excluded — not at some notional figure and not at what the dealer would have paid to buy the trip himself. Each dealer's aggregate for the year crosses ₹20,000, so Section 194R applies to each of them individually, and the tax is 10% of ₹48,000, that is ₹4,800 per dealer, before or at the time of providing the benefit.
Because the benefit is entirely in kind, the company cannot withhold ₹4,800 from a payment that does not exist. It must either collect ₹4,800 from each dealer before booking the trip, which is rare in practice, or gross up the benefit and bear the tax itself, in which case the value on which tax is computed rises above ₹48,000 to account for the tax borne. If the company instead values the trip at a lower notional figure not supported by the purchase invoice, and a TDS survey queries it, the short deduction becomes the company's own liability with interest, quite apart from penalty: under Section 201 for FY 2025-26 benefits, and under section 398, with interest under section 398(3)(a), for FY 2026-27 defaults.
Run the same scheme for doctors and the tax answer is not the starting point. Sponsoring a healthcare professional's travel and hospitality in return for prescribing volume is prohibited under the Uniform Code for Pharmaceutical Marketing Practices, 2024 and the NMC regulations, and in Apex Laboratories Pvt Ltd v. DCIT the Supreme Court held that expenditure on freebies to doctors is disallowed under Explanation 1 to Section 37(1) because it is incurred for a purpose prohibited by law. The same principle is carried into section 34 of the Income-tax Act, 2025 from tax year 2026-27. Deducting TDS under Section 194R does not legitimise the arrangement and does not restore the deduction. There is a second wrinkle even where the benefit is lawful: Circular No. 12/2022 says that where a free sample or benefit is given to a doctor employed by a hospital, the benefit is treated as provided to the hospital, which becomes the deductee and may in turn treat it as a perquisite of the employee under Section 17 with tax deducted under Section 192 (section 17 and section 392 of the 2025 Act from FY 2026-27). Get the deductee wrong and the deduction is wrong however carefully the value was computed.
Common mistakes and red flags
- Treating every dealer/doctor scheme item as automatically outside 194R because it is called a “discount” in internal scheme documents, without checking whether it is genuinely reflected in the invoice/sale price.
- Not tracking the ₹20,000 aggregate threshold per recipient across the full financial year and across multiple scheme types — a series of small benefits to the same person can cumulatively cross the threshold even if no single item does.
- Valuing non-cash benefits at an arbitrary figure instead of applying the Circular 12/2022 hierarchy — fair market value, displaced by purchase price where the item was bought in and by the price charged to customers where it was manufactured, in each case excluding GST.
- Treating a healthcare-professional scheme as a pure TDS question. Sponsorship of doctors is barred by the UCPMP 2024 and the NMC regulations and the spend is disallowed under Section 37(1) (section 34 of the 2025 Act) per Apex Laboratories; deducting tax on it fixes neither problem.
- Deducting against the doctor rather than the hospital where the recipient is a hospital employee — Circular 12/2022 treats the benefit as provided to the hospital.
- Reimbursing recipient expenses without requiring bills in the payer's own name, which weakens the “genuine reimbursement, not a benefit” position if challenged.
- Failing to gross up correctly (or at all) where a wholly-in-kind benefit is provided and the recipient has not separately paid the tax, leaving the payer short-deducted.
- Applying 194R to a non-resident dealer, or ignoring section 195 for that dealer altogether.
- Applying an ad hoc, scheme-by-scheme judgment call each time instead of a documented, consistent classification policy across the organisation's incentive programmes.
What should you do now
Every business running dealer, distributor, doctor or channel-partner incentive schemes should map each scheme item into one of three buckets and document the basis for each: (i) a price reduction reflected in invoicing, outside 194R; (ii) a genuine expense reimbursement with bills in the payer's name, outside 194R; or (iii) a benefit or perquisite, valued on the Circular 12/2022 hierarchy — fair market value, displaced by the purchase price where the item was bought in and by the price charged to customers where it was manufactured, excluding GST — with 194R applied, TDS deducted where possible, or the benefit grossed up and tax borne where it is wholly in kind. This classification should be built into the scheme design itself, not decided retrospectively when a TDS survey or assessment raises the question, since ad hoc, inconsistent treatment across similar scheme items is precisely the pattern that draws scrutiny. Finance teams should also maintain a running per-recipient tally against the ₹20,000 threshold, since the obligation is cumulative across the year, not per-transaction, and should confirm for each scheme who the deductee actually is — for a benefit given to a doctor employed by a hospital, Circular 12/2022 treats the hospital as the recipient. Where the scheme is aimed at healthcare professionals, clear it against the UCPMP 2024 and the disallowance in Apex Laboratories before the TDS question is reached at all.
Frequently asked questions
What is the TDS rate and threshold under Section 194R?
10% TDS applies on the value of a business benefit or perquisite provided to a resident, once the aggregate value of such benefits to that recipient exceeds ₹20,000 in a financial year. The threshold is cumulative across the year and across different scheme items to the same recipient, not per transaction. Both the rate and the ₹20,000 threshold continue unchanged under Section 393(1), Table: Sl. No. 8(iv) of the Income-tax Act, 2025.
Are ordinary trade discounts covered by Section 194R?
No. CBDT has clarified that discounts and rebates given in the ordinary course of business, and reflected in the invoice or effectively reducing the sale price, are not “benefits” under Section 194R. Incentives given after the sale is complete, such as trip vouchers or gadgets tied to a sales target, are generally treated differently and do attract 194R.
How should a non-cash benefit like a sponsored trip be valued for TDS purposes?
CBDT Circular No. 12/2022 lays down the rule: the value is the fair market value of the benefit, except that where the provider purchased it before providing it the value is the purchase price, and where the provider manufactured it the value is the price charged to its customers. GST is excluded from that value. So a sponsored trip bought in from a travel agent is valued at what the sponsor paid, supported by the invoice — not at what the recipient would have paid to buy the same trip. Only an item that was neither purchased nor manufactured by the provider, and has no established market price, is genuinely open.
What happens if the benefit is entirely in kind with no cash component?
The provider must either ensure the recipient has paid tax on the value of the benefit before it is released, or gross up the benefit and bear the tax itself, since there is no cash payment from which TDS can otherwise be withheld.
Is reimbursement of a dealer's genuine business expense covered by Section 194R?
Generally no, provided it is a genuine reimbursement of expenditure incurred by the recipient on the payer's behalf, ideally with bills in the payer's own name. Where documentation is thin, the department may recharacterise the payment as a disguised benefit and bring it within 194R.
Does Section 194R still apply under the new Income-tax Act 2025?
Yes. From tax year 2026-27 the obligation sits in Section 393(1), Table: Sl. No. 8(iv) of the Income-tax Act, 2025, which consolidates the TDS provisions into one section with a table. The rate remains 10% and the threshold remains ₹20,000. Benefits provided up to 31 March 2026 stay under Section 194R and the 1961 procedure. For benefits from 1 April 2026, check the timing condition in section 393(1), Table S.No. 8(iv), and the related rules before redesigning when tax is deducted or collected.
Does Section 194R apply to incentives given to non-resident dealers?
No. Section 194R, and its successor row in section 393(1), covers benefits provided to residents. A benefit or incentive given to a non-resident dealer or distributor is tested under section 195 (section 393(2) from 1 April 2026) and any applicable tax treaty instead.
TDS Return FilingIncome Tax FilingTalk to us
This article is general information for educational purposes, not an opinion on any specific case or a substitute for professional advice; the legal position summarised here can change, so please verify current status and consult a qualified professional before acting on your own facts.